Abstract
Individuals with trisomy 21, also known as Down syndrome (DS), develop a clinical syndrome including almost identical neuropathological characteristics of Alzheimers disease (AD) observed in non-DS individuals. The main difference is the early age of onset of AD pathology in individuals with DS, with high incidence of clinical symptoms in the late 40- early 50 years of age. The neuropathology of AD in persons with DS is superimposed with the developmental abnormalities causing alterations of neuronal morphology and function. Despite the ubiquitous occurrence of AD neuropathology, clinical signs of dementia do not occur in all adults with DS even at older ages. Phenotype analysis of DS mouse models has revealed a differential age-related neurodegenerative pattern that correlates with specific biochemical and molecular alterations at the cellular level. In fact, several individual genes found in trisomy in DS have been functionally related to neuronal degeneration. Thus, mouse models overexpressing HSA21 gene(s) are fundamental to understand the neurodegenerative process in DS, as described in the present review. In addition, these models might allow to define and evaluate potential drug targets and to develop therapeutic strategies that may interfere or delay the onset of AD.
Keywords: Down syndrome, Alzheimer's disease, neurodegeneration, HSA21 genes, mouse models
CNS & Neurological Disorders - Drug Targets
Title: Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome
Volume: 9 Issue: 4
Author(s): Cristina Fillat, Mara Dierssen, Maria Martinez de Lagran and Xavier Altafaj
Affiliation:
Keywords: Down syndrome, Alzheimer's disease, neurodegeneration, HSA21 genes, mouse models
Abstract: Individuals with trisomy 21, also known as Down syndrome (DS), develop a clinical syndrome including almost identical neuropathological characteristics of Alzheimers disease (AD) observed in non-DS individuals. The main difference is the early age of onset of AD pathology in individuals with DS, with high incidence of clinical symptoms in the late 40- early 50 years of age. The neuropathology of AD in persons with DS is superimposed with the developmental abnormalities causing alterations of neuronal morphology and function. Despite the ubiquitous occurrence of AD neuropathology, clinical signs of dementia do not occur in all adults with DS even at older ages. Phenotype analysis of DS mouse models has revealed a differential age-related neurodegenerative pattern that correlates with specific biochemical and molecular alterations at the cellular level. In fact, several individual genes found in trisomy in DS have been functionally related to neuronal degeneration. Thus, mouse models overexpressing HSA21 gene(s) are fundamental to understand the neurodegenerative process in DS, as described in the present review. In addition, these models might allow to define and evaluate potential drug targets and to develop therapeutic strategies that may interfere or delay the onset of AD.
Export Options
About this article
Cite this article as:
Fillat Cristina, Dierssen Mara, Martinez de Lagran Maria and Altafaj Xavier, Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome, CNS & Neurological Disorders - Drug Targets 2010; 9 (4) . https://dx.doi.org/10.2174/187152710791556159
DOI https://dx.doi.org/10.2174/187152710791556159 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Anti-Cancer Agents in Medicinal Chemistry Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry Beta-Amyloid, Oxidative Stress and Down Syndrome
Current Alzheimer Research Neuroactive Molecules in the Brains of Nonhuman Primates and Their Therapeutic Application to Neurodegenerative Disorders
Central Nervous System Agents in Medicinal Chemistry Nitric Oxide’s Involvement in the Spectrum of Psychotic Disorders
Current Medicinal Chemistry Epigenetic Regulation of Memory-Therapeutic Potential for Disorders
Current Neuropharmacology Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease
Current Alzheimer Research Stroke as a Cause of Death in Death Certificates of Patients with Dementia: A Cohort Study from the Swedish Dementia Registry
Current Alzheimer Research Applying Melanopic Lux to Measure Biological Light Effects on Melatonin Suppression and Subjective Sleepiness
Current Alzheimer Research Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Involvement of the Serotonergic System in Cognitive and Behavioral Symptoms of Alzheimers Disease
Current Psychiatry Reviews Electrochemical Biosensor for the Detection of Glycated Albumin
Current Alzheimer Research Novel Insights for Multiple Sclerosis and Demyelinating Disorders with Apoptosis, Autophagy, FoxO, and mTOR
Current Neurovascular Research Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Stability in Cognitive Function Over 18 Years: Prevalence and Predictors among Older Mexican Americans
Current Alzheimer Research Biological Markers in Older People at Risk of Mobility Limitations
Current Pharmaceutical Design Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery The Essential Mechanisms of Aging: What Have We Learnt in Ten Years?
Current Topics in Medicinal Chemistry The Effects of Aerobic Exercise on Cognitive Function of Alzheimer's Disease Patients
CNS & Neurological Disorders - Drug Targets